The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 24.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 125%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $161.
Axcelis Technologies, Inc. ACLS
Clears both ethical standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Axcelis Technologies, Inc.
read at $136.42
Axcelis Technologies, Inc. holds its Distribution at $136.42.
- PHPhase · the trend structure carries the Distribution label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 15 days |
| Price | $136.42 |
| Valuation | 42.37 trailing · 28.14 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.87 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
| Revenue growth | 3.30% |
| Profit margin | 11.93% |
| Debt to equity | 6.75 |
| Analyst consensus | Buy · 3 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Ion Implant Tools Ride a Semiconductor Rollercoaster
Every wafer that needs doping still passes through an ion implanter, and Axcelis builds some of the best. Yet the whole supply chain moves with chipmakers capital spending cycles that swing hard and fast. At 28 times forward earnings and revenue barely rising 3 percent, the shares sit well above our fair value with little margin of safety.
The business clears our ethical screen and shows a 12 percent profit margin plus 10 percent return on equity, but those returns sit inside an industry that rarely sustains them at the top of the cycle. Three analysts still call it a buy with a 173 dollar median target, yet the low single-digit growth and unknown competitive edge leave little room for error once equipment orders slow.
Cyclical names trading on elevated multiples often look reasonable until earnings peak and the multiple compresses at the same time. Currency moves and sudden foundry cuts add further volatility that the current price does not appear to discount. Analysis, not advice.
| Forward P/E | 28.1x expensive even after accounting for its growth |
| Trailing P/E | 42.4x expensive — the price assumes strong growth ahead |
| Revenue growth | 3.3% slow but positive growth |
| Profit margin | 11.9% thin but positive margins |
| Return on equity | 9.7% a modest return on shareholder capital |
| Debt to equity | 0.07 minimal debt — a conservative balance sheet |
| Current ratio | 4.59 comfortably covers its short-term bills |
| Beta | 1.87 much more volatile than the market |
| Market cap | $4.2B |
| Employees | 1,465 |
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in ACLS's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
ACLS trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 125%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $161.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 125%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $161.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $165.08 | -3.4% | · | $966 | -3.4% |
| 2 months | $110.37 | +44.5% | · | $1,445 | +44.5% |
| 3 months | $85.18 | +87.2% | · | $1,872 | +87.2% |
| 6 months | $89.08 | +79.0% | · | $1,790 | +79.0% |
| 1 year | $70.76 | +125.4% | · | $2,254 | +125.4% |
| 2 years | $127.20 | +25.4% | · | $1,254 | +25.4% |
| 3 years | $172.61 | -7.6% | · | $924 | -7.6% |
| 5 years | $41.51 | +284.2% | · | $3,842 | +284.2% |
Historical returns from market close data. Past performance does not guarantee future results.